ANSWER: C

Rationale:

S phase (synthesis) is the portion of the cell cycle in which the cell replicates its entire DNA content, ensuring that each of the two daughter cells produced by the subsequent division receives a complete copy of the genome. This is the conceptual anchor for an entire class of chemotherapy drugs: antimetabolites act specifically during S phase because that is when DNA is actively being synthesized and the cell is most vulnerable to agents that disrupt nucleotide supply or DNA replication. Understanding when DNA is made explains why certain drugs must be present at a particular point in the cycle to work.

• Option A: Option A is incorrect because G1 (gap 1) is the biosynthetic preparation phase that precedes DNA replication; its duration is highly variable among cell types and is the main determinant of overall cycle length, but no DNA copying occurs during G1.
• Option B: Option B is incorrect because M phase (mitosis) is when the already-duplicated chromosomes are physically separated into two daughter cells; the DNA was copied earlier, in S phase.
• Option D: Option D is incorrect because G2 (gap 2) is the premitotic interval in which the cell prepares for mitosis after DNA synthesis is already complete.
• Option E: Option E is incorrect because G0 is the reversible quiescent state outside the active cycle; cells in G0 are not replicating DNA at all, which is precisely why they form a reservoir of cells that escape cycle-specific chemotherapy.

ANSWER: B

Rationale:

Antimetabolites are S-phase-specific agents because their mechanism depends on the cell actively synthesizing DNA. Methotrexate blocks dihydrofolate reductase and starves the cell of the reduced folates needed to make purine and thymidine nucleotides, while 5-fluorouracil interferes with thymidylate synthase and the supply of thymidine. Both mechanisms are only lethal to a cell that is trying to replicate its DNA at the time of exposure. This is why S-phase-specific agents show a plateau on their dose-response curve and are best given as prolonged infusions or repeated doses: only cells that happen to be in S phase during the exposure window are killed, so extending the exposure catches more cells as they enter S phase. The concept links drug class to cell cycle phase to optimal dosing schedule.

• Option A: Option A is incorrect because disrupting the mitotic spindle in M phase is the mechanism of the vinca alkaloids and taxanes, not the antimetabolites.
• Option C: Option C is incorrect because G0 cells are not synthesizing DNA and are therefore relatively resistant to antimetabolites; quiescent cells are a classic reservoir of cells that survive cycle-specific therapy.
• Option D: Option D is incorrect because G2 is premitotic preparation, not DNA synthesis, and is not the target phase of antimetabolites.
• Option E: Option E describes cycle-nonspecific agents such as the alkylating agents and platinum compounds, which kill cells regardless of cycle position — the opposite of the antimetabolites described in the stem.

ANSWER: D

Rationale:

The log-kill hypothesis states that a given dose of a chemotherapy agent kills a constant fraction of the tumor cells present, not a constant number. If a dose produces a 3-log kill (99.9 percent), it reduces a population of 10 to the 10th power cells to 10 to the 7th power, and a second equivalent dose reduces that to 10 to the 4th power, and so on — each cycle removes the same percentage rather than the same absolute count. This fractional-kill concept has two profound clinical consequences taught throughout oncology: first, cure requires driving the surviving population below one viable cell, which usually demands repeated cycles; and second, treating when tumor burden is lowest (for example, in the adjuvant setting after surgery) maximizes the chance that a fixed number of fractional-kill cycles can eradicate the disease before resistance or cumulative toxicity intervenes.

• Option A: Option A inverts the central teaching: the kill is a constant fraction, not a constant number — this is the single most common misconception the log-kill model was formulated to correct.
• Option B: Option B is incorrect because the constant-fraction relationship is what the hypothesis asserts; it does not predict greater fractional kill in larger tumors, and in fact large tumors are harder to cure because of lower growth fraction and greater absolute cell number.
• Option C: Option C describes the emergence of acquired resistance, which is a separate phenomenon and not what the log-kill hypothesis itself states.
• Option E: Option E is incorrect because the model relates each dose to a fraction of the cells present at that moment; the size and timing of individual doses matter, which is why scheduling and dose intensity are clinically important.

ANSWER: A

Rationale:

Cells in G0 are metabolically active but are not progressing through the division cycle, and they represent a critical reservoir of cells that survive cycle-specific chemotherapy. Agents such as antimetabolites (S-phase) and vinca alkaloids (M-phase) can only kill cells that are actively traversing the relevant phase; a quiescent G0 cell is doing neither DNA synthesis nor mitosis and therefore escapes these drugs. The clinical danger is that surviving G0 cells can later re-enter the active cycle and repopulate the tumor, producing relapse after an apparently complete response. This concept underlies several strategies taught later in oncology — including the use of cycle-nonspecific agents that kill regardless of cycle position, and scheduling approaches that try to recruit G0 cells back into the cycle where they become vulnerable.

• Option B: Option B is incorrect because G0 cells are by definition not dividing; the rapidly dividing, highly chemosensitive cells are those in the active cycle with a high growth fraction.
• Option C: Option C is incorrect because the G0 state is reversible — these cells can re-enter the cycle, which is exactly why they threaten cure.
• Option D: Option D inverts the pharmacology: S-phase agents require active DNA synthesis to work, so resting G0 cells are relatively resistant to antimetabolites, not preferentially killed by them.
• Option E: Option E incorrectly claims a biological impossibility; G0 cells are intact, living cells with normal membranes, and their resistance has nothing to do with drug entry across the membrane.

ANSWER: E

Rationale:

A vesicant is a drug that, if it extravasates into the tissue surrounding the vein, causes severe tissue destruction, blistering, and potentially deep necrosis that can require surgical debridement or skin grafting. The most important clinical vesicants include the anthracyclines (doxorubicin, daunorubicin), the vinca alkaloids (vincristine, vinblastine), mechlorethamine, and mitomycin C. The anthracyclines are especially dangerous because doxorubicin binds tissue DNA and is released slowly from necrotic tissue, producing progressive injury that continues to advance for weeks after the initial event. Recognizing which agents are vesicants is the foundation for understanding extravasation as an oncologic emergency and for knowing which antidotes and measures apply — concepts built upon in later questions in this set.

• Option A: Option A describes a trivial, self-limited reaction and understates the danger that defines a vesicant.
• Option B: Option B is incorrect because vesicants are intravenous agents; the term refers to tissue toxicity on leakage, not to the route restriction.
• Option C: Option C describes an irritant, which causes pain, inflammation, and phlebitis but does not cause tissue necrosis — the key distinction from a vesicant.
• Option D: Option D is incorrect because vesicant status is a property of the drug's tissue toxicity, not of the type of venous access used; in fact, central access is often chosen precisely because a drug is a vesicant.

ANSWER: B

Rationale:

P-glycoprotein (P-gp), the product of the MDR1 gene (also called ABCB1) and a member of the ATP-binding cassette transporter superfamily, is an energy-dependent efflux pump embedded in the plasma membrane. It uses the energy of ATP hydrolysis to actively pump a broad range of structurally diverse hydrophobic drugs out of the cell, lowering the intracellular concentration below the cytotoxic threshold. Because its substrate range is wide — including anthracyclines, vinca alkaloids, taxanes, and etoposide — overexpression of a single pump can produce resistance to several structurally unrelated drugs at once, which is the meaning of the term multidrug resistance. This efflux concept is the anchor for understanding why combination regimens are designed to include agents that are not all P-gp substrates.

• Option A: Option A describes metabolic inactivation (for example, conjugation reactions), a different resistance category, not the action of P-gp.
• Option C: Option C describes target mutation or amplification, such as altered topoisomerase II or amplified dihydrofolate reductase, which is also a distinct mechanism.
• Option D: Option D describes enhanced DNA repair, another separate resistance pathway.
• Option E: Option E is incorrect in this context: although P-gp in the normal intestinal epithelium does limit oral drug absorption, the resistance mechanism in tumor cells is active efflux that pumps drug out of the cancer cell itself, not blockade of intestinal absorption.

ANSWER: C

Rationale:

Lipophilic (fat-soluble) cytotoxic agents such as the nitrosoureas and the anthracyclines have very large volumes of distribution because they partition extensively into adipose tissue and other peripheral compartments, leaving relatively little drug in the plasma at any moment. A large volume of distribution means the drug is widely sequestered in tissues rather than confined to the blood. This property has practical consequences: it allows these agents to penetrate widely (the lipophilic nitrosoureas, for example, are among the few drugs that cross the blood-brain barrier well), and it means plasma concentration alone can underrepresent the total amount of drug in the body. The concept connects a basic physicochemical property — lipophilicity — to a measurable pharmacokinetic parameter and to clinical behavior such as tissue penetration.

• Option A: Option A is incorrect because hydrophilic agents such as carboplatin and methotrexate have small volumes of distribution that approximate the extracellular fluid volume; they stay closer to the bloodstream, the opposite of a large Vd.
• Option B: Option B is incorrect because heavy plasma protein binding tends to retain drug in the vascular compartment, which is associated with a smaller, not larger, volume of distribution.
• Option D: Option D is incorrect because renal clearance is a route of elimination and does not by itself increase tissue distribution.
• Option E: Option E is incorrect because the volume of distribution is a property of how the drug partitions into tissues, not of the speed of injection.

ANSWER: A

Rationale:

Febrile neutropenia is defined by the combination of fever and a critically low neutrophil count: a single temperature above 38.3 degrees Celsius (101 degrees Fahrenheit), or a temperature above 38.0 degrees Celsius (100.4 degrees Fahrenheit) sustained over one hour, in a patient whose absolute neutrophil count is below 500 cells per microliter — or below 1,000 and expected to fall below 500 within 48 hours. Both elements are required. It is a medical emergency because the patient has lost the neutrophil defense against bacterial infection, carries a meaningful mortality risk, and requires broad-spectrum antibacterial therapy within one hour of presentation. Learning the precise definition is what allows a clinician to recognize the emergency and act before the patient deteriorates.

• Option B: Option B is incorrect because fever alone, without documented neutropenia, does not meet the definition; the dangerously low neutrophil count is the element that makes the situation an emergency.
• Option C: Option C is incorrect because neutropenia without fever is not febrile neutropenia; the fever is the signal that infection may be present in a host who cannot mount a normal inflammatory response.
• Option D: Option D inverts the key laboratory finding: the defining feature is a very low neutrophil count, not a high white blood cell count.
• Option E: Option E is incorrect because the danger period is during the neutrophil nadir; fever after full count recovery does not constitute febrile neutropenia.

ANSWER: D

Rationale:

The metabolic picture of tumor lysis syndrome follows directly from the rapid release of intracellular contents when many tumor cells die at once: hyperkalemia from released intracellular potassium, hyperphosphatemia from released intracellular phosphate, and hyperuricemia from the breakdown of released nucleic acids (purines are catabolized to uric acid). The high phosphate then binds calcium and precipitates, producing a secondary hypocalcemia. The dangerous consequences flow from these derangements: hyperkalemia can cause fatal cardiac arrhythmias, uric acid can crystallize in the renal tubules and cause acute kidney injury, and hypocalcemia can cause tetany or seizures. Knowing the quartet (high potassium, high phosphate, high uric acid, low calcium) lets a clinician anticipate, monitor for, and prevent the syndrome in high-risk patients.

• Option A: Option A reverses the true pattern and is incorrect on every value.
• Option B: Option B does not match the syndrome; sodium and glucose are not the defining disturbances, and uric acid is elevated, not low.
• Option C: Option C is incorrect because potassium and phosphate are elevated in TLS, not low, and calcium is low, not high.
• Option E: Option E is incorrect because calcium is low (not high) and phosphate is high (not low) in tumor lysis syndrome, even though it correctly notes the elevated uric acid.

ANSWER: B

Rationale:

Cytarabine is S-phase specific, so at any single moment it can only kill the fraction of cells that happen to be synthesizing DNA — typically only 20 to 30 percent of the cycling population. A one-time bolus would miss all the cells that enter S phase minutes to hours later. A continuous seven-day infusion maintains cytotoxic concentrations throughout the period, so that each dividing cell in the marrow is exposed to drug at the moment it enters S phase. This is the practical application of the cycle-specific concept introduced earlier in this set: for a phase-specific agent, prolonging exposure (not simply raising the single dose) is what increases cell kill, because the dose-response curve plateaus once the cells currently in the sensitive phase are killed. Scheduling, not dose escalation alone, explains why continuous-infusion cytarabine produces deeper remissions.

• Option A: Option A is incorrect because the rationale is about timing of exposure relative to the cell cycle, not about reducing total dose; the infusion is designed to maximize exposure of cells passing through S phase.
• Option C: Option C is incorrect because schedule cannot change a drug's mechanism: cytarabine remains S-phase specific and does not become able to kill resting G0 cells.
• Option D: Option D incorrectly dismisses a genuine pharmacological principle; the schedule is mechanistically driven, not a matter of convenience.
• Option E: Option E is incorrect because continuous infusion does not bypass P-glycoprotein; the efflux pump operates regardless of whether the drug is delivered by bolus or infusion.

ANSWER: E

Rationale:

The Gompertzian model holds that small tumors grow nearly exponentially with a high growth fraction, while large tumors slow down: as the mass enlarges, the growth fraction falls and the doubling time lengthens because blood supply cannot keep pace. The clinical consequence — and the rationale for adjuvant therapy — is that microscopic deposits remaining after surgery are small, have a high growth fraction, and are dividing rapidly, which makes them more sensitive to cycle-active chemotherapy than the original bulky tumor ever was. Treating this microscopic disease when its growth fraction is highest, and combined with the log-kill principle that fractional kill is most likely to achieve cure at low tumor burden, is why adjuvant chemotherapy can eradicate disease that is invisible on imaging. This connects the growth-kinetics concept to a concrete treatment decision.

• Option A: Option A is incorrect because adjuvant therapy is specifically directed at undetectable microscopic disease, not at visible residual tumor; the entire premise is that imaging shows no detectable disease.
• Option B: Option B states the opposite of the model: bulky tumors have a low growth fraction and are comparatively resistant, whereas small tumors have the high growth fraction.
• Option C: Option C is incorrect because chemotherapy is not limited to invisible tumors; it can treat detectable disease as well, though microscopic disease is more chemosensitive per the kinetics.
• Option D: Option D incorrectly contradicts the central teaching of the Gompertzian model: the growth fraction is not fixed but falls as tumor size increases, which is exactly why timing matters.

ANSWER: A

Rationale:

Carboplatin is eliminated almost entirely by renal excretion, so its clearance tracks closely with glomerular filtration rate. The Calvert formula exploits this by setting the dose to achieve a defined target AUC (drug exposure over time) as a function of the patient's GFR. Targeting exposure directly, rather than estimating it from body surface area, corrects a systematic problem: body-size-based dosing systematically underdoses patients with high renal clearance (who eliminate the drug quickly) and overdoses patients with impaired renal function (who eliminate it slowly and would otherwise accumulate toxic levels). This makes carboplatin one of the best-established examples of pharmacokinetically guided dosing in routine oncology, and it illustrates the broader principle that matching dose to the actual route of elimination improves both safety and consistency.

• Option B: Option B is incorrect because carboplatin is cleared by the kidney, not the liver, and GFR measures renal function, not hepatic function.
• Option C: Option C is incorrect because AUC-based dosing concerns the calculation of the dose, not the route of administration; carboplatin is given intravenously.
• Option D: Option D inverts the logic of the formula: the Calvert approach depends critically on knowing the patient's GFR — kidney function is the central input.
• Option E: Option E is incorrect because carboplatin exposure correlates with both efficacy and toxicity, which is precisely why controlling the AUC matters.

ANSWER: C

Rationale:

If resistance to drug A arises independently of resistance to drug B, then the probability that a single tumor cell is resistant to both at once is the product of the two probabilities. For example, if resistance to each drug occurs at a frequency of about one in a million (10 to the minus 6), the chance of a cell being resistant to both simultaneously is roughly one in a trillion (10 to the minus 12) — below the number of cells present even in microscopic disease. This multiplicative argument is the mathematical foundation of combination chemotherapy: using agents with non-cross-resistant mechanisms makes it statistically very unlikely that any single resistant subclone can survive all the drugs together. It builds directly on the resistance concepts introduced earlier and explains why curative regimens combine mechanistically distinct drugs.

• Option A: Option A overstates the principle: combination dramatically reduces, but does not absolutely guarantee elimination of, the probability of a doubly resistant cell.
• Option B: Option B is incorrect because resistance suppression — not dose reduction — is the core rationale described here; in fact combinations are designed to allow near-full doses of each agent.
• Option D: Option D inverts the logic: combining non-cross-resistant drugs lowers, not raises, the probability that a cell resists the whole regimen.
• Option E: Option E is incorrect because the probability of surviving treatment is much lower with multiple independent agents than with one, which is the entire point of the multiplicative argument.

ANSWER: D

Rationale:

G-CSF stimulates neutrophil precursors in the marrow to proliferate and differentiate. The timing rule exists because actively proliferating cells are precisely the cells most vulnerable to cycle-specific cytotoxic agents. If G-CSF is started while chemotherapy drug levels are still high, it pushes the precursor population into active division at the very moment those dividing cells can be killed by residual drug — which can paradoxically deepen and prolong the myelosuppression the G-CSF was meant to shorten. Waiting roughly 24 to 72 hours after the last chemotherapy dose lets drug levels fall before the precursors are recruited into the cycle. This question connects the cell-cycle vulnerability concept from Section 1 to a concrete supportive-care timing decision.

• Option A: Option A is incorrect because the problem is not chemical inactivation of G-CSF; it is the biological vulnerability of stimulated, dividing precursors to the cytotoxic drug.
• Option B: Option B is incorrect because premature excretion is not the issue; the concern is the interaction between proliferating precursors and residual cytotoxic drug.
• Option C: Option C is incorrect because G-CSF does not block chemotherapy from reaching the tumor; the two act on different targets.
• Option E: Option E is incorrect because G-CSF is given after chemotherapy, not before; the rule concerns how soon after, not a reversal of the order.

ANSWER: B

Rationale:

The two phases of chemotherapy-induced nausea are driven by different mediators, which is why antiemetic regimens combine drug classes. Acute nausea (within 24 hours) is driven mainly by serotonin (5-HT3) released from enterochromaffin cells in the gut, which stimulates vagal afferent 5-HT3 receptors and activates the vomiting center — this is why 5-HT3 receptor antagonists such as ondansetron are central to acute control. Delayed nausea (24 to 120 hours) is driven predominantly by substance P binding neurokinin-1 (NK-1) receptors in the brainstem, which is why NK-1 antagonists such as aprepitant are added for delayed-phase coverage. Matching the mediator to the phase explains the rationale for the multidrug antiemetic regimens (5-HT3 antagonist plus NK-1 antagonist plus dexamethasone) used for highly emetogenic chemotherapy.

• Option A: Option A is incorrect because dopamine is not the predominant mediator of either acute or delayed chemotherapy-induced nausea in this framework; serotonin and substance P are.
• Option C: Option C reverses the correct pairing: serotonin dominates the acute phase and substance P the delayed phase, not the other way around.
• Option D: Option D is incorrect because histamine and acetylcholine are the relevant mediators in motion sickness and some other nausea contexts, not the predominant drivers of acute and delayed chemotherapy-induced nausea.
• Option E: Option E is incorrect because both phases involve well-defined neurotransmitter-receptor pathways, which is exactly what makes targeted antiemetics effective.

ANSWER: A

Rationale:

The central nervous system is the most clinically important sanctuary site — an anatomical compartment poorly penetrated by systemically administered drugs because the blood-brain barrier, formed by tight junctions between cerebral endothelial cells, restricts entry of most hydrophilic and high-molecular-weight agents. Leukemia cells can survive in the CNS even when systemic therapy has cleared the marrow and blood, then later seed a relapse. Intrathecal administration injects drug directly into the cerebrospinal fluid by lumbar puncture, bypassing the barrier entirely and delivering cytotoxic concentrations to the protected compartment. This bridges the sanctuary-site concept from the pharmacokinetics section to a real treatment decision in leukemia: the reason for CNS-directed therapy is anatomical drug access, not a different disease.

• Option B: Option B is incorrect because systemic chemotherapy is in fact effective against leukemia in the marrow and blood — the very reason remission was achieved; the issue is only the protected CNS compartment.
• Option C: Option C is incorrect because the cerebrospinal fluid is not a site of drug metabolism; intrathecal dosing is about access, not breakdown.
• Option D: Option D is incorrect because intrathecal therapy targets sanctuary disease, not nausea, which is managed with antiemetics.
• Option E: Option E inverts the physiology: the blood-brain barrier excludes most drugs rather than concentrating them, which is precisely why the CNS is a sanctuary.

ANSWER: E

Rationale:

Anthracycline extravasation is a genuine oncologic emergency because doxorubicin binds tissue DNA and is released slowly from necrotic tissue, producing injury that progresses for weeks. The correct response is to stop the infusion immediately and administer dexrazoxane intravenously within six hours — the only FDA-approved antidote for anthracycline extravasation, which works by chelating iron (reducing iron-mediated free-radical damage) and inhibiting topoisomerase II in the affected tissue. The six-hour window is not flexible; delay sharply reduces efficacy. Cooling is specifically contraindicated when dexrazoxane is used because it reduces local blood flow and therefore dexrazoxane delivery to the tissue. This question applies the vesicant concept from Section 1 to an emergency decision, integrating drug identity, mechanism, and time-critical management.

• Option A: Option A describes the management of vinca alkaloid extravasation (warm compress plus hyaluronidase); applied to an anthracycline it is wrong, and cooling-versus-warming differs by agent.
• Option B: Option B is incorrect and dangerous because anthracyclines are vesicants, not irritants, and untreated extravasation causes progressive necrosis.
• Option C: Option C describes the antidote for mechlorethamine extravasation (sodium thiosulfate), not anthracyclines.
• Option D: Option D is incorrect because the infusion must be stopped immediately, not continued; continuing delivers more vesicant into the tissue.

ANSWER: C

Rationale:

Rasburicase converts uric acid to allantoin, and the reaction generates hydrogen peroxide as a byproduct. In a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cells lack the capacity to regenerate the reduced glutathione needed to neutralize hydrogen peroxide, so the oxidative stress causes severe, potentially life-threatening hemolytic anemia. For this reason G6PD deficiency is an absolute contraindication to rasburicase, and G6PD status should be checked before administration in patients whose ancestry places them at higher risk. When testing is not yet available in an urgent situation, allopurinol plus aggressive hydration is the safer default while results are pending. This question integrates the tumor lysis concept from Section 1 with a specific, mechanism-based drug safety rule — exactly the kind of precise discrimination a bridge question requires.

• Option A: Option A is incorrect because hypertension is not a contraindication to rasburicase and the drug is not characterized by causing hypertensive emergencies.
• Option B: Option B is incorrect because seasonal allergic rhinitis is not a contraindication; the dangerous interaction is specifically with the oxidative chemistry of G6PD-deficient erythrocytes.
• Option D: Option D is incorrect because mild iron-deficiency anemia is unrelated to the rasburicase mechanism and the drug does not depend on iron supplementation.
• Option E: Option E is incorrect because a history of kidney stones is not an absolute contraindication; rasburicase actually lowers uric acid and is used to prevent uric acid nephropathy.

ANSWER: D

Rationale:

Choosing agents with non-overlapping dose-limiting toxicities lets each drug be given at or near its full single-agent dose, because their worst toxicities fall on different organs rather than stacking on one. In CHOP, cyclophosphamide and doxorubicin dose-limit primarily on myelosuppression (and doxorubicin additionally on cumulative cardiotoxicity), vincristine dose-limits on peripheral neuropathy with little myelosuppression, and prednisone adds anti-lymphoma activity with essentially no myelosuppression. Because the toxicities do not all converge on the marrow, the regimen can deliver four independent mechanisms of action at effective doses, preserving the dose intensity that drives cure. This applies the combination-chemotherapy principle to a specific, real regimen and requires distinguishing dose intensity from simple dose reduction.

• Option A: Option A inverts the principle: the goal is non-overlapping toxicities, so the drugs do not share the same dose-limiting organ.
• Option B: Option B is incorrect because the aim is to maintain full effective doses of each agent, not to shrink the total dose; reducing doses would compromise efficacy.
• Option C: Option C overstates the result; combination chemotherapy still has substantial toxicity, just distributed across organs rather than concentrated.
• Option E: Option E is incorrect because cost reduction is not the rationale; preserving dose intensity and suppressing resistance are the design goals.

ANSWER: B

Rationale:

Dose intensity is the broader concept — the amount of drug delivered per unit time (for example, mg per square meter per week) — and it can be increased either by raising the per-cycle dose or by shortening the interval between cycles. Dose density is the specific strategy of shortening the inter-cycle interval while holding the per-cycle dose constant, which raises intensity by reducing the recovery time during which residual tumor cells regrow. This applies the Norton-Simon reasoning: compressing the interval prevents exponential regrowth of microscopic disease between cycles, when the growth fraction of surviving cells is highest. Dose-dense scheduling requires G-CSF support to be feasible, because the shortened interval would otherwise cause cumulative myelosuppression. Distinguishing these two terms — easily conflated — is exactly the precise discrimination a bridge question demands, and it builds on the Gompertzian and G-CSF concepts already established.

• Option A: Option A reverses both definitions: dose density shortens (not lengthens) the interval, and massive per-cycle escalation with stem cell rescue is high-dose therapy, a different strategy.
• Option C: Option C is incorrect because the two terms are not interchangeable; dose density is one specific way of increasing dose intensity.
• Option D: Option D is incorrect because neither term refers to infusion-bag concentration or body weight; both describe the rate of drug delivery over time.
• Option E: Option E is incorrect because dose density does not mean reducing the dose, and dose intensity is not defined by the number of different drugs used.

ANSWER: A

Rationale:

Target amplification produces resistance by overwhelming the drug with an excess of its target. Methotrexate inhibits dihydrofolate reductase, but if the tumor cell amplifies the DHFR gene and manufactures far more enzyme than normal, the achievable methotrexate concentration can no longer inhibit all of it. The residual uninhibited fraction of DHFR is enough to keep regenerating reduced folates, sustaining purine and thymidine synthesis and therefore DNA replication. This is the prototypic example of resistance by target amplification, distinct from the efflux mechanism of P-glycoprotein or the metabolic-inactivation mechanisms covered earlier. The question requires the student to discriminate among the resistance categories established in Section 1 and apply the correct one to a specific drug-enzyme pair.

• Option B: Option B describes drug efflux, the mechanism of P-glycoprotein (an ATP-driven pump), not the function of DHFR, which is a metabolic enzyme and does not transport drugs.
• Option C: Option C is incorrect because DHFR does not chemically degrade methotrexate; resistance here arises from sheer excess of the target enzyme, not drug destruction.
• Option D: Option D is incorrect because DHFR amplification operates inside the tumor cell and does not affect intestinal absorption of the drug.
• Option E: Option E is incorrect because DHFR does not activate methotrexate; methotrexate is administered in its active form and inhibits DHFR directly.

ANSWER: E

Rationale:

Cycle-specific chemotherapy kills cells while they traverse a particular phase, so a tumor in which nearly all cells are actively cycling presents far more vulnerable targets at any moment than a tumor in which most cells are quiescent. Burkitt lymphoma, with a growth fraction approaching 90 to 100 percent, is therefore exquisitely sensitive to cycle-specific agents, whereas chronic lymphocytic leukemia, with a growth fraction below 10 percent, is comparatively resistant to those agents (though it may still respond to drugs that act regardless of cycle position, such as alkylating agents). This is a direct application of the growth-fraction concept from Section 1 and reinforces why the same drugs produce dramatically different responses across tumor types — closing the set on the kinetic principle it opened with.

• Option A: Option A reverses the relationship: the low growth fraction of chronic lymphocytic leukemia makes it comparatively resistant to cycle-specific drugs, not the most sensitive.
• Option B: Option B incorrectly contradicts the central teaching that growth fraction strongly influences chemosensitivity to cycle-specific agents.
• Option C: Option C is incorrect because growth fraction predicts chemosensitivity, not a surgical outcome, and both tumors are in fact treated with chemotherapy.
• Option D: Option D is incorrect because a high growth fraction increases sensitivity to cycle-specific drugs rather than decreasing it; the claim about faster repair in rapidly dividing cells is not the operative principle here.